Update on FDG-PET in pediatric lymphoma

Area of Science:

• Pediatric oncology
• Nuclear medicine
• Medical imaging

Background:

• Lymphoma is the third most common childhood malignancy, categorized into pediatric Hodgkin lymphoma (P-HL) and pediatric non-Hodgkin lymphoma (P-NHL).
• P-HL treatment combines chemotherapy and radiotherapy, with FDG-PET integral for over 20 years in staging and response assessment.
• P-NHL is primarily treated with chemotherapy, where FDG-PET's current role is subordinate.

Purpose of the Study:

• To present the current status of FDG-PET in pediatric lymphoma management.
• To detail the application of FDG-PET in staging and response assessment for pediatric lymphomas.
• To discuss challenges, pitfalls, and future directions of FDG-PET in pediatric lymphoma.

Main Methods:

• Review of current literature and clinical practice regarding FDG-PET use in pediatric lymphoma.
• Analysis of FDG-PET's role in staging and response assessment for both P-HL and P-NHL.
• Discussion of existing challenges and future potential of FDG-PET in pediatric lymphoma treatment.

Main Results:

• FDG-PET is well-established and integral in P-HL for staging and chemotherapy response assessment, guiding treatment intensity.
• FDG-PET plays a subordinate role in P-NHL treatment, with its potential for management largely underutilized.
• Key aspects covered include staging, response assessment, challenges, and future developments of FDG-PET in pediatric lymphoma.

Conclusions:

• FDG-PET is essential for optimizing P-HL treatment through precise staging and response evaluation.
• Significant untapped potential exists for FDG-PET to enhance P-NHL treatment strategies.
• Further research and integration are needed to fully leverage FDG-PET's capabilities in pediatric lymphoma care.